Literature DB >> 7537511

Development of lymphoid hyperplasia in transgenic mice expressing the HIV tat gene.

C Vellutini1, N Horschowski, V Philippon, D Gambarelli, K A Nave, P Filippi.   

Abstract

During HIV infection, individuals experience multiorgan disorders such as adenopathy, splenomegaly, and lung and brain diseases. There is an increasing body of evidence that the HIV trans-activating tat gene product possesses multiple activities. First, it can activate several cellular genes; second, in its extracellular soluble form, it plays the role of growth factor in some cells such as Kaposi's sarcoma cells. Thus, we introduced the HIV tat gene, under the control of the cellular proteolipoprotein promoter, into the germline of mice and demonstrate that, when expressed, the tat gene product induces lymphoid hyperplasia in spleen, lymph nodes, and lung, as is observed in AIDS patients, but not in the brain or testes. Our findings indicate that HIV, through some of its genes, directly participates in the pathogenesis of AIDS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537511     DOI: 10.1089/aid.1995.11.21

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  13 in total

1.  Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge.

Authors:  S S Cohen; C Li; L Ding; Y Cao; A B Pardee; E M Shevach; D I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Selective up-regulation of functional CXCR4 expression in erythroid cells by HIV-1 Tat protein.

Authors:  D Gibellini; M C Re; F Vitone; N Rizzo; C Maldini; M La Placa; G Zauli
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

3.  Transgenic dissection of HIV genes involved in lymphoid depletion.

Authors:  B T Tinkle; H Ueda; L Ngo; P A Luciw; K Shaw; C A Rosen; G Jay
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 4.  Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.

Authors:  Haijun Han; Zhongli Yang; Sulie L Chang; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-13       Impact factor: 4.147

Review 5.  Doxycycline-inducible and astrocyte-specific HIV-1 Tat transgenic mice (iTat) as an HIV/neuroAIDS model.

Authors:  Dianne Langford; Byung Oh Kim; Wei Zou; Yan Fan; Pejman Rahimain; Ying Liu; Johnny J He
Journal:  J Neurovirol       Date:  2017-11-15       Impact factor: 2.643

6.  Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline.

Authors:  Byung Oh Kim; Ying Liu; Yiwen Ruan; Zao C Xu; Laurel Schantz; Johnny J He
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

7.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.

Authors:  W Reid; M Sadowska; F Denaro; S Rao; J Foulke; N Hayes; O Jones; D Doodnauth; H Davis; A Sill; P O'Driscoll; D Huso; T Fouts; G Lewis; M Hill; R Kamin-Lewis; C Wei; P Ray; R C Gallo; M Reitz; J Bryant
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 8.  New insights into HIV-1-primary skin disorders.

Authors:  Filiberto Cedeno-Laurent; Minerva Gómez-Flores; Nora Mendez; Jesús Ancer-Rodríguez; Joseph L Bryant; Anthony A Gaspari; Jose R Trujillo
Journal:  J Int AIDS Soc       Date:  2011-01-24       Impact factor: 5.396

9.  Transgenic mice expressing the nucleoprotein of Borna disease virus in either neurons or astrocytes: decreased susceptibility to homotypic infection and disease.

Authors:  Mathias Rauer; Jürgen Götz; Daniel Schuppli; Peter Staeheli; Jürgen Hausmann
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Adult AIDS-like disease in a novel inducible human immunodeficiency virus type 1 Nef transgenic mouse model: CD4+ T-cell activation is Nef dependent and can occur in the absence of lymphophenia.

Authors:  Mir Munir Ahmed Rahim; Pavel Chrobak; Chunyan Hu; Zaher Hanna; Paul Jolicoeur
Journal:  J Virol       Date:  2009-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.